

Table 4. NEUROINFLAMMATION AND CYTOKINE-TARGETED INTERVENTIONS : Targeting IFN- γ

Target	Drug	Main Indications	CT Number , Title, Study Protocol	Neurological Implications
IFN- γ	Emapalumab Anti-IFN- γ antibody	•Primary Hemophagocytic Lymphohistiocytosis (HLH)	NCT04324021 Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. Interventional Phase 2/3	In patients affected by Adenosine Deaminase Deficiency- Severe Combined Immunodeficiency (ADA-SCID), emapalumab reduced the size of brain lesions caused by CNS Tuberculosis infection (Tucci et al., 2020).